Role of Short-Term Radiotherapy in Cancer of Large Bowel
Ontology highlight
ABSTRACT: Interventions: Short course radiotherapy with 25 Gy in 5 fractions with concurrent chemotherapy regimen including Capecitabine 850mg/m2/bid for 5 days and Oxaliplatin 85mg/m2/day for 1 day then one cycle chemotherapy with XELOX regimen (Capecitabine 1000mg/m2/bid for 14 days and Oxaliplatin 130mg/m2/day for 1 day) 3 weeks after completion of radiotherapy then surgery 8 weeks after the radiotherapy last session..;Treatment - Other;Short course radiotherapy with 25 Gy in 5 fractions with concurrent chemotherapy regimen including Capecitabine 850mg/m2/bid for 5 days and Oxaliplatin 85mg/m2/day for 1 day then one cycle chemotherapy with XELOX regimen (Capecitabine 1000mg/m2/bid for 14 days and Oxaliplatin 130mg/m2/day for 1 day) 3 weeks after completion of radiotherapy then surgery 8 weeks after the radiotherapy last session.
Primary outcome(s): Complications. Timepoint: At the Initiation of Radiotherapy up to one month after surgery. Method of measurement: Common terminology criteria for cancer related therapy adverse events.
Study Design: Randomization: N/A, Blinding: Not blinded, Placebo: Not used, Assignment: Single, Purpose: Treatment.
DISEASE(S): Malignant Neoplasm Of Rectum,Rectal Adenocarcinoma
PROVIDER: 2491836 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA